Investors

Press Releases

Endonovo Therapeutics Issues Open Letter and Update to Its Shareholders
Endonovo Evaluating Therapeutic Potential of Non-Invasive Electroceutical for Treatment of Kidney Disease
Endonovo Evaluating Therapeutic Potential of Non-Invasive Electroceutical for Treatment of Non-Alcoholic Steatohepatitis (NASH)
Endonovo Evaluating Therapeutic Potential of Non-Invasive Electroceutical Device for Treatment of Critical Limb Ischemia
Endonovo Therapeutics Files a New Patent Application on Method to Treat Tissues and Organs Using Its Non-Invasive Electroceutical Technology
Endonovo Evaluating Therapeutic Potential of Non-Invasive Electroceutical Device Following Myocardial Infarction
Endonovo Signs Term Sheet for $5 Million to Redeem All Outstanding Convertible Notes and Prepare to Uplist Its Common Stock
Endonovo Therapeutics (ENDV): Targeting $20+ Billion Market for In Vitro ADME and Toxicology Testing
Endonovo Therapeutics Announces Registration Statement on Form S-1 has been Declared Effective
Endonovo Therapeutics Issues Corporate Update
RSS
Show All